Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hyperlipoproteinemia Type II | 27 | 2024 | 373 | 5.530 |
Why?
|
Dyslipidemias | 15 | 2023 | 849 | 4.990 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 20 | 2023 | 546 | 3.360 |
Why?
|
Cardiovascular Diseases | 44 | 2024 | 15165 | 2.750 |
Why?
|
Hypercholesterolemia | 13 | 2024 | 1151 | 2.460 |
Why?
|
Coronary Aneurysm | 12 | 2023 | 237 | 2.300 |
Why?
|
Cholesterol, LDL | 23 | 2024 | 2356 | 2.140 |
Why?
|
Mass Screening | 18 | 2024 | 5255 | 2.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2022 | 3255 | 1.810 |
Why?
|
American Heart Association | 17 | 2022 | 1056 | 1.640 |
Why?
|
Atherosclerosis | 15 | 2024 | 3445 | 1.570 |
Why?
|
Cholesterol | 16 | 2023 | 2917 | 1.570 |
Why?
|
Triglycerides | 14 | 2022 | 2454 | 1.530 |
Why?
|
Lipids | 14 | 2023 | 3305 | 1.410 |
Why?
|
Health Behavior | 6 | 2021 | 2636 | 1.360 |
Why?
|
Cardiology | 10 | 2022 | 1668 | 1.260 |
Why?
|
Anticholesteremic Agents | 10 | 2023 | 979 | 1.220 |
Why?
|
Child | 91 | 2024 | 77709 | 1.110 |
Why?
|
Hypertension | 14 | 2023 | 8480 | 1.110 |
Why?
|
Hyperlipidemias | 7 | 2022 | 789 | 1.110 |
Why?
|
Adolescent | 81 | 2024 | 85781 | 1.080 |
Why?
|
Nutrition Surveys | 11 | 2023 | 1660 | 1.000 |
Why?
|
Preventive Health Services | 6 | 2021 | 575 | 1.000 |
Why?
|
Health Status Indicators | 2 | 2021 | 969 | 0.890 |
Why?
|
Guideline Adherence | 5 | 2017 | 2266 | 0.830 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2020 | 3923 | 0.820 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 2 | 2023 | 236 | 0.810 |
Why?
|
Pediatrics | 11 | 2022 | 3475 | 0.770 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2022 | 3336 | 0.760 |
Why?
|
Preventive Medicine | 2 | 2020 | 264 | 0.720 |
Why?
|
Life Style | 9 | 2022 | 3835 | 0.720 |
Why?
|
Systemic Inflammatory Response Syndrome | 6 | 2023 | 612 | 0.720 |
Why?
|
Practice Guidelines as Topic | 12 | 2020 | 7279 | 0.690 |
Why?
|
Directive Counseling | 1 | 2021 | 166 | 0.690 |
Why?
|
Prevalence | 15 | 2022 | 15226 | 0.680 |
Why?
|
Risk Factors | 52 | 2024 | 72290 | 0.660 |
Why?
|
Awareness | 2 | 2020 | 640 | 0.630 |
Why?
|
Humans | 168 | 2024 | 744343 | 0.620 |
Why?
|
Heart Diseases | 7 | 2021 | 2788 | 0.620 |
Why?
|
Hyperglycemia | 2 | 2022 | 1373 | 0.600 |
Why?
|
Health Status | 5 | 2020 | 4034 | 0.580 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2018 | 235 | 0.560 |
Why?
|
United States | 48 | 2023 | 69872 | 0.560 |
Why?
|
Alanine Transaminase | 1 | 2019 | 592 | 0.550 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2019 | 397 | 0.530 |
Why?
|
Hypertriglyceridemia | 3 | 2019 | 293 | 0.530 |
Why?
|
Creatine Kinase | 1 | 2017 | 694 | 0.510 |
Why?
|
Obesity | 20 | 2023 | 12745 | 0.490 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2013 | 314 | 0.490 |
Why?
|
Young Adult | 42 | 2024 | 56430 | 0.480 |
Why?
|
Diet, Fat-Restricted | 1 | 2017 | 320 | 0.480 |
Why?
|
Female | 89 | 2024 | 380194 | 0.470 |
Why?
|
Boston | 12 | 2023 | 9313 | 0.470 |
Why?
|
Urban Health | 1 | 2016 | 547 | 0.460 |
Why?
|
Women's Health | 3 | 2021 | 2034 | 0.460 |
Why?
|
Cholesterol, HDL | 7 | 2022 | 1814 | 0.460 |
Why?
|
Male | 82 | 2024 | 350118 | 0.450 |
Why?
|
Patient Transfer | 1 | 2020 | 761 | 0.450 |
Why?
|
Echocardiography | 8 | 2023 | 5102 | 0.450 |
Why?
|
Biosensing Techniques | 1 | 2019 | 668 | 0.440 |
Why?
|
Coronary Vessels | 4 | 2020 | 3107 | 0.440 |
Why?
|
Muscular Diseases | 1 | 2017 | 556 | 0.430 |
Why?
|
Immunoglobulins, Intravenous | 7 | 2020 | 652 | 0.430 |
Why?
|
Tobacco Smoke Pollution | 2 | 2016 | 816 | 0.420 |
Why?
|
Risk Reduction Behavior | 9 | 2020 | 1125 | 0.410 |
Why?
|
Income | 2 | 2022 | 1913 | 0.400 |
Why?
|
Heart Defects, Congenital | 4 | 2024 | 4584 | 0.400 |
Why?
|
Risk Assessment | 17 | 2023 | 23338 | 0.390 |
Why?
|
Blood Pressure | 12 | 2023 | 8554 | 0.390 |
Why?
|
Child, Preschool | 28 | 2023 | 41006 | 0.390 |
Why?
|
Equipment Design | 1 | 2019 | 3582 | 0.380 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 3843 | 0.380 |
Why?
|
Coronary Artery Disease | 6 | 2024 | 6487 | 0.380 |
Why?
|
C-Reactive Protein | 8 | 2020 | 3778 | 0.370 |
Why?
|
Longevity | 1 | 2018 | 1070 | 0.360 |
Why?
|
Diabetes Mellitus, Type 2 | 7 | 2020 | 11725 | 0.360 |
Why?
|
Energy Intake | 2 | 2019 | 2148 | 0.360 |
Why?
|
Thrombosis | 3 | 2020 | 2968 | 0.350 |
Why?
|
Body Mass Index | 12 | 2020 | 12720 | 0.350 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.350 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2019 | 1344 | 0.340 |
Why?
|
Pulse | 1 | 2009 | 229 | 0.330 |
Why?
|
Dietary Supplements | 3 | 2020 | 3297 | 0.330 |
Why?
|
Health Promotion | 4 | 2021 | 2205 | 0.330 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 882 | 0.320 |
Why?
|
Research Report | 3 | 2016 | 355 | 0.310 |
Why?
|
Counseling | 4 | 2022 | 1523 | 0.300 |
Why?
|
Advisory Committees | 3 | 2017 | 775 | 0.300 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2012 | 859 | 0.290 |
Why?
|
Delayed Diagnosis | 2 | 2021 | 441 | 0.290 |
Why?
|
Age Factors | 10 | 2020 | 18370 | 0.280 |
Why?
|
Policy Making | 2 | 2020 | 554 | 0.270 |
Why?
|
Adult | 39 | 2023 | 214055 | 0.270 |
Why?
|
Adiposity | 3 | 2018 | 1807 | 0.260 |
Why?
|
Fever | 3 | 2023 | 1616 | 0.250 |
Why?
|
Myocarditis | 2 | 2022 | 771 | 0.240 |
Why?
|
Retrospective Studies | 21 | 2024 | 77449 | 0.240 |
Why?
|
Infant | 17 | 2021 | 35136 | 0.230 |
Why?
|
Follow-Up Studies | 12 | 2022 | 39050 | 0.230 |
Why?
|
Cross-Sectional Studies | 11 | 2022 | 25043 | 0.230 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3610 | 0.220 |
Why?
|
Feeding Behavior | 1 | 2015 | 3188 | 0.220 |
Why?
|
Genetic Testing | 7 | 2024 | 3444 | 0.210 |
Why?
|
Immunization | 2 | 2017 | 1256 | 0.210 |
Why?
|
Apolipoproteins B | 3 | 2019 | 374 | 0.210 |
Why?
|
Endothelium, Vascular | 3 | 2019 | 4456 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1855 | 0.200 |
Why?
|
Adipocytes | 1 | 2008 | 1184 | 0.190 |
Why?
|
Food | 2 | 2016 | 771 | 0.190 |
Why?
|
Registries | 6 | 2023 | 8089 | 0.190 |
Why?
|
Health Surveys | 5 | 2016 | 4037 | 0.190 |
Why?
|
Overweight | 2 | 2017 | 2371 | 0.190 |
Why?
|
Warfarin | 2 | 2020 | 1496 | 0.180 |
Why?
|
Prospective Studies | 12 | 2021 | 53288 | 0.180 |
Why?
|
Health Policy | 1 | 2013 | 2661 | 0.180 |
Why?
|
Primary Prevention | 2 | 2021 | 1167 | 0.180 |
Why?
|
Homozygote | 4 | 2023 | 1785 | 0.180 |
Why?
|
Hospitals, Pediatric | 2 | 2024 | 1775 | 0.180 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 297 | 0.170 |
Why?
|
Attitude to Health | 2 | 2020 | 2052 | 0.170 |
Why?
|
Blood Component Removal | 1 | 2020 | 125 | 0.170 |
Why?
|
Atrioventricular Block | 1 | 2020 | 120 | 0.170 |
Why?
|
Diet, Sodium-Restricted | 1 | 2020 | 287 | 0.160 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 339 | 0.160 |
Why?
|
Folic Acid Antagonists | 1 | 1998 | 84 | 0.160 |
Why?
|
Self Report | 3 | 2018 | 3558 | 0.160 |
Why?
|
Canada | 2 | 2020 | 2065 | 0.160 |
Why?
|
Chemoprevention | 1 | 2020 | 319 | 0.160 |
Why?
|
Brachial Artery | 2 | 2010 | 369 | 0.160 |
Why?
|
Aortic Valve Insufficiency | 1 | 2022 | 579 | 0.150 |
Why?
|
Ventricular Remodeling | 2 | 2017 | 1224 | 0.150 |
Why?
|
Blood Pressure Determination | 2 | 2018 | 634 | 0.150 |
Why?
|
Proprotein Convertases | 2 | 2016 | 95 | 0.150 |
Why?
|
Liver Function Tests | 1 | 2019 | 528 | 0.150 |
Why?
|
Goals | 1 | 2022 | 706 | 0.150 |
Why?
|
Treatment Outcome | 12 | 2022 | 63114 | 0.150 |
Why?
|
Intraoperative Complications | 1 | 2004 | 1198 | 0.150 |
Why?
|
Hypolipidemic Agents | 1 | 2021 | 604 | 0.150 |
Why?
|
Aortic Coarctation | 1 | 2019 | 281 | 0.140 |
Why?
|
Comorbidity | 7 | 2018 | 10388 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 541 | 0.140 |
Why?
|
Insulin Resistance | 3 | 2017 | 3864 | 0.140 |
Why?
|
Sex Factors | 4 | 2019 | 10397 | 0.140 |
Why?
|
Health Status Disparities | 2 | 2019 | 1797 | 0.140 |
Why?
|
Public Health | 3 | 2020 | 2603 | 0.140 |
Why?
|
Incidence | 8 | 2021 | 20947 | 0.140 |
Why?
|
Private Sector | 1 | 2019 | 392 | 0.140 |
Why?
|
India | 1 | 2022 | 2197 | 0.140 |
Why?
|
Pacemaker, Artificial | 1 | 2021 | 816 | 0.140 |
Why?
|
Educational Status | 1 | 2024 | 2540 | 0.130 |
Why?
|
Expert Testimony | 1 | 2018 | 356 | 0.130 |
Why?
|
Financing, Government | 1 | 2019 | 468 | 0.130 |
Why?
|
Developmental Disabilities | 1 | 2004 | 1456 | 0.130 |
Why?
|
Focus Groups | 1 | 2020 | 1321 | 0.130 |
Why?
|
Coronary Disease | 4 | 2023 | 6077 | 0.130 |
Why?
|
Censuses | 1 | 2016 | 200 | 0.130 |
Why?
|
Aorta | 2 | 2022 | 2061 | 0.130 |
Why?
|
Lipodystrophy | 1 | 2016 | 147 | 0.130 |
Why?
|
Research Subjects | 1 | 2017 | 239 | 0.120 |
Why?
|
Societies, Medical | 4 | 2019 | 3743 | 0.120 |
Why?
|
Glycerol Kinase | 1 | 2014 | 16 | 0.120 |
Why?
|
Genetic Counseling | 1 | 2018 | 600 | 0.120 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2016 | 303 | 0.120 |
Why?
|
Morbidity | 1 | 2020 | 1769 | 0.120 |
Why?
|
Carbohydrate Metabolism, Inborn Errors | 1 | 2014 | 31 | 0.120 |
Why?
|
Glycerol-3-Phosphate Dehydrogenase (NAD+) | 1 | 2014 | 13 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2022 | 1073 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2020 | 9959 | 0.120 |
Why?
|
Hepatomegaly | 1 | 2014 | 85 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
Lipoproteins | 1 | 2019 | 878 | 0.120 |
Why?
|
Glucose | 2 | 2022 | 4397 | 0.120 |
Why?
|
Drug Recalls | 1 | 2013 | 17 | 0.120 |
Why?
|
Benchmarking | 2 | 2018 | 1042 | 0.120 |
Why?
|
Utilization Review | 1 | 2015 | 392 | 0.110 |
Why?
|
Perception | 1 | 2020 | 1198 | 0.110 |
Why?
|
Nervous System Diseases | 1 | 2004 | 1622 | 0.110 |
Why?
|
Neoplasms | 1 | 2022 | 21683 | 0.110 |
Why?
|
Ventricular Function, Left | 4 | 2022 | 3670 | 0.110 |
Why?
|
Decision Making | 3 | 2016 | 3887 | 0.110 |
Why?
|
Inflammation | 3 | 2023 | 10638 | 0.110 |
Why?
|
Patient Identification Systems | 1 | 2013 | 79 | 0.110 |
Why?
|
Stroke | 4 | 2018 | 9981 | 0.110 |
Why?
|
Burnout, Professional | 1 | 2022 | 694 | 0.110 |
Why?
|
Cities | 1 | 2015 | 513 | 0.110 |
Why?
|
Down-Regulation | 2 | 2020 | 3002 | 0.110 |
Why?
|
Health Planning Guidelines | 1 | 2013 | 163 | 0.110 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12245 | 0.110 |
Why?
|
Middle Aged | 13 | 2024 | 213383 | 0.110 |
Why?
|
Serine Endopeptidases | 2 | 2016 | 1072 | 0.110 |
Why?
|
Risk | 5 | 2019 | 9687 | 0.110 |
Why?
|
Parents | 5 | 2017 | 3407 | 0.110 |
Why?
|
Drug Contamination | 1 | 2013 | 147 | 0.110 |
Why?
|
Data Interpretation, Statistical | 4 | 2018 | 2716 | 0.110 |
Why?
|
Nephrotic Syndrome | 1 | 2016 | 389 | 0.110 |
Why?
|
Defibrillators, Implantable | 1 | 2021 | 1440 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Massachusetts | 3 | 2021 | 8663 | 0.100 |
Why?
|
Heptanoic Acids | 1 | 2013 | 343 | 0.100 |
Why?
|
Blood Glucose | 4 | 2017 | 6256 | 0.100 |
Why?
|
Motivation | 1 | 2021 | 1971 | 0.100 |
Why?
|
Fasting | 3 | 2007 | 1593 | 0.100 |
Why?
|
Lipid Metabolism | 2 | 2012 | 1889 | 0.100 |
Why?
|
Aortic Valve Stenosis | 2 | 2022 | 1965 | 0.100 |
Why?
|
Cooperative Behavior | 1 | 2018 | 1504 | 0.100 |
Why?
|
Aspirin | 2 | 2019 | 3282 | 0.100 |
Why?
|
Primary Health Care | 3 | 2016 | 4558 | 0.100 |
Why?
|
Circadian Rhythm | 1 | 2023 | 2624 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2016 | 681 | 0.100 |
Why?
|
Regression Analysis | 3 | 2019 | 6459 | 0.100 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2011 | 115 | 0.090 |
Why?
|
Patient Care | 1 | 2016 | 640 | 0.090 |
Why?
|
Social Class | 1 | 2019 | 1999 | 0.090 |
Why?
|
Tunica Media | 1 | 2010 | 113 | 0.090 |
Why?
|
Exercise | 4 | 2023 | 5615 | 0.090 |
Why?
|
Remission, Spontaneous | 1 | 2010 | 382 | 0.090 |
Why?
|
Length of Stay | 2 | 2021 | 6309 | 0.090 |
Why?
|
Sinusitis | 1 | 1998 | 923 | 0.090 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7785 | 0.090 |
Why?
|
Guidelines as Topic | 2 | 2016 | 1405 | 0.090 |
Why?
|
Anion Exchange Resins | 1 | 2008 | 10 | 0.080 |
Why?
|
Logistic Models | 3 | 2021 | 13408 | 0.080 |
Why?
|
Child Health Services | 2 | 2013 | 667 | 0.080 |
Why?
|
Diabetic Angiopathies | 1 | 2014 | 818 | 0.080 |
Why?
|
Population Surveillance | 1 | 2020 | 2616 | 0.080 |
Why?
|
Cardiac Surgical Procedures | 1 | 2004 | 3537 | 0.080 |
Why?
|
Health Services Research | 1 | 2017 | 1836 | 0.080 |
Why?
|
Anticoagulants | 3 | 2020 | 4599 | 0.080 |
Why?
|
Insulin | 3 | 2022 | 6580 | 0.080 |
Why?
|
Drug Therapy | 1 | 2012 | 497 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3584 | 0.080 |
Why?
|
Breast Feeding | 1 | 2016 | 1338 | 0.080 |
Why?
|
Disease Progression | 4 | 2022 | 13284 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.080 |
Why?
|
Reference Values | 3 | 2017 | 4982 | 0.080 |
Why?
|
Tunica Intima | 1 | 2010 | 464 | 0.080 |
Why?
|
Fatty Liver | 1 | 2014 | 727 | 0.080 |
Why?
|
Medication Therapy Management | 2 | 2018 | 127 | 0.080 |
Why?
|
Infant, Newborn | 5 | 2020 | 25625 | 0.080 |
Why?
|
Leptin | 1 | 2016 | 1599 | 0.080 |
Why?
|
Hyperemia | 1 | 2009 | 225 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2018 | 2708 | 0.080 |
Why?
|
Anthropometry | 2 | 2019 | 1350 | 0.070 |
Why?
|
Drug Prescriptions | 1 | 2017 | 1637 | 0.070 |
Why?
|
Pyrroles | 1 | 2013 | 1146 | 0.070 |
Why?
|
Clinical Protocols | 1 | 2013 | 1462 | 0.070 |
Why?
|
Consensus | 3 | 2022 | 2959 | 0.070 |
Why?
|
Motor Activity | 2 | 2016 | 2714 | 0.070 |
Why?
|
Health Care Surveys | 1 | 2014 | 2453 | 0.070 |
Why?
|
Postprandial Period | 1 | 2008 | 292 | 0.070 |
Why?
|
Patient Care Planning | 1 | 2012 | 921 | 0.070 |
Why?
|
Regional Blood Flow | 1 | 2010 | 1525 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 7913 | 0.070 |
Why?
|
Fatty Acids, Nonesterified | 1 | 2008 | 402 | 0.070 |
Why?
|
Cell Size | 1 | 2008 | 643 | 0.070 |
Why?
|
Adipokines | 1 | 2008 | 319 | 0.070 |
Why?
|
Fingers | 1 | 2009 | 513 | 0.070 |
Why?
|
Myocardium | 2 | 2022 | 4776 | 0.070 |
Why?
|
Students | 1 | 2015 | 1654 | 0.070 |
Why?
|
Carotid Arteries | 1 | 2010 | 952 | 0.070 |
Why?
|
Pilot Projects | 2 | 2015 | 8324 | 0.070 |
Why?
|
Quality Improvement | 2 | 2018 | 3749 | 0.070 |
Why?
|
Pregnancy | 3 | 2023 | 29144 | 0.060 |
Why?
|
Weight Loss | 1 | 2017 | 2622 | 0.060 |
Why?
|
Feasibility Studies | 2 | 2020 | 5078 | 0.060 |
Why?
|
Secondary Prevention | 1 | 2012 | 1530 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12354 | 0.060 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.060 |
Why?
|
Receptors, LDL | 2 | 2018 | 475 | 0.060 |
Why?
|
Research Design | 1 | 2020 | 5987 | 0.060 |
Why?
|
Pandemics | 5 | 2022 | 8388 | 0.060 |
Why?
|
Inflammation Mediators | 2 | 2013 | 1889 | 0.060 |
Why?
|
Case-Control Studies | 5 | 2021 | 21746 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9274 | 0.060 |
Why?
|
Aged | 7 | 2022 | 163280 | 0.060 |
Why?
|
Internet | 1 | 2015 | 3064 | 0.060 |
Why?
|
Waist Circumference | 2 | 2017 | 917 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 10943 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17446 | 0.050 |
Why?
|
Steroid 12-alpha-Hydroxylase | 1 | 2022 | 9 | 0.050 |
Why?
|
Animals | 7 | 2022 | 168757 | 0.050 |
Why?
|
Patient Education as Topic | 1 | 2012 | 2278 | 0.050 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 1144 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10262 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7659 | 0.050 |
Why?
|
Sitosterols | 1 | 2020 | 9 | 0.050 |
Why?
|
Predictive Value of Tests | 3 | 2022 | 15076 | 0.050 |
Why?
|
Reproducibility of Results | 4 | 2019 | 19905 | 0.050 |
Why?
|
Electronic Health Records | 2 | 2017 | 4468 | 0.050 |
Why?
|
MicroRNAs | 1 | 2017 | 3752 | 0.050 |
Why?
|
Immunologic Factors | 2 | 2020 | 1580 | 0.050 |
Why?
|
Phytosterols | 1 | 2020 | 64 | 0.050 |
Why?
|
Phenotype | 4 | 2020 | 16365 | 0.050 |
Why?
|
Xanthomatosis | 1 | 2020 | 32 | 0.050 |
Why?
|
Lipoproteins, HDL | 1 | 2004 | 638 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 1998 | 7181 | 0.050 |
Why?
|
New Zealand | 1 | 2020 | 355 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15540 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2014 | 12026 | 0.040 |
Why?
|
Bile Acids and Salts | 1 | 2022 | 367 | 0.040 |
Why?
|
Terminology as Topic | 2 | 2017 | 1547 | 0.040 |
Why?
|
Macrophage Activation Syndrome | 1 | 2020 | 111 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 634 | 0.040 |
Why?
|
Simvastatin | 1 | 2022 | 360 | 0.040 |
Why?
|
Cardiac Imaging Techniques | 1 | 2021 | 269 | 0.040 |
Why?
|
Cohort Studies | 5 | 2024 | 40561 | 0.040 |
Why?
|
Pain Measurement | 1 | 2009 | 3420 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3309 | 0.040 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2017 | 964 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Cost of Illness | 2 | 2020 | 1859 | 0.040 |
Why?
|
Liver | 3 | 2022 | 7474 | 0.040 |
Why?
|
Job Satisfaction | 1 | 2022 | 535 | 0.040 |
Why?
|
Receptor, Insulin | 1 | 2022 | 846 | 0.040 |
Why?
|
Troponin | 1 | 2021 | 524 | 0.040 |
Why?
|
Qualitative Research | 2 | 2017 | 2682 | 0.040 |
Why?
|
Legislation, Drug | 1 | 2019 | 206 | 0.040 |
Why?
|
Interleukin-17 | 1 | 2023 | 899 | 0.040 |
Why?
|
Amoxicillin | 1 | 1998 | 170 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3528 | 0.040 |
Why?
|
Australia | 1 | 2020 | 1170 | 0.040 |
Why?
|
Arteriosclerosis | 1 | 2002 | 1092 | 0.040 |
Why?
|
Coronary Vessel Anomalies | 1 | 2020 | 314 | 0.040 |
Why?
|
Mississippi | 1 | 2017 | 88 | 0.040 |
Why?
|
Organizational Policy | 1 | 2019 | 429 | 0.040 |
Why?
|
Gadolinium | 1 | 2022 | 952 | 0.040 |
Why?
|
Food Safety | 1 | 2016 | 22 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2023 | 1725 | 0.040 |
Why?
|
Oxidative Stress | 1 | 2008 | 3086 | 0.040 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2016 | 63 | 0.040 |
Why?
|
Hemorrhage | 2 | 2020 | 3461 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2008 | 2899 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2022 | 2029 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2020 | 594 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2007 | 6895 | 0.030 |
Why?
|
Penicillins | 1 | 1998 | 380 | 0.030 |
Why?
|
Quality Control | 1 | 1998 | 841 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2017 | 367 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 12951 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 29063 | 0.030 |
Why?
|
Steroids | 1 | 2020 | 930 | 0.030 |
Why?
|
Stroke Volume | 2 | 2021 | 5007 | 0.030 |
Why?
|
California | 1 | 2019 | 1402 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2020 | 1200 | 0.030 |
Why?
|
Mice, Obese | 1 | 2016 | 424 | 0.030 |
Why?
|
Mitochondria | 1 | 2008 | 3520 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2019 | 57776 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13881 | 0.030 |
Why?
|
Smoking Cessation | 2 | 2017 | 2071 | 0.030 |
Why?
|
Carnitine O-Palmitoyltransferase | 1 | 2014 | 86 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1609 | 0.030 |
Why?
|
Drug Approval | 1 | 2019 | 742 | 0.030 |
Why?
|
Social Change | 1 | 2013 | 153 | 0.030 |
Why?
|
Heart Failure | 1 | 2017 | 10900 | 0.030 |
Why?
|
Smoking | 2 | 2017 | 8987 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1573 | 0.030 |
Why?
|
Podocytes | 1 | 2016 | 396 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2008 | 10481 | 0.030 |
Why?
|
School Health Services | 1 | 2015 | 375 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2203 | 0.030 |
Why?
|
Chronic Disease | 2 | 2017 | 9146 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2017 | 1285 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2022 | 3760 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1584 | 0.030 |
Why?
|
History, 20th Century | 1 | 2019 | 2740 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 1996 | 1344 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 13989 | 0.020 |
Why?
|
Organ Size | 1 | 2016 | 2252 | 0.020 |
Why?
|
Research Personnel | 1 | 2016 | 573 | 0.020 |
Why?
|
Self Care | 1 | 2016 | 786 | 0.020 |
Why?
|
Physical Fitness | 1 | 2015 | 733 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2020 | 3200 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3638 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6489 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2107 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1339 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2019 | 2050 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2016 | 1425 | 0.020 |
Why?
|
Electroencephalography | 1 | 2004 | 6150 | 0.020 |
Why?
|
Linear Models | 1 | 2019 | 5952 | 0.020 |
Why?
|
Contrast Media | 1 | 2022 | 5300 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2018 | 2046 | 0.020 |
Why?
|
Cytokines | 1 | 2023 | 7322 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3870 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4751 | 0.020 |
Why?
|
Heart | 1 | 2021 | 4467 | 0.020 |
Why?
|
Electrocardiography | 1 | 2021 | 6442 | 0.020 |
Why?
|
Vaccines | 1 | 2017 | 822 | 0.020 |
Why?
|
Diabetes Mellitus | 2 | 2017 | 5751 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5179 | 0.020 |
Why?
|
Transposition of Great Vessels | 1 | 2012 | 588 | 0.020 |
Why?
|
Acute Disease | 1 | 1998 | 7149 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4420 | 0.020 |
Why?
|
Data Collection | 1 | 2016 | 3341 | 0.020 |
Why?
|
Heterozygote | 1 | 2014 | 2804 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4669 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2016 | 6622 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3022 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2017 | 2585 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
Gene Deletion | 1 | 2014 | 2751 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2014 | 1941 | 0.020 |
Why?
|
Child Development | 1 | 2016 | 2223 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 35421 | 0.020 |
Why?
|
Vaccination | 1 | 2017 | 3278 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2016 | 3821 | 0.010 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2012 | 1265 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5137 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7799 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2014 | 4803 | 0.010 |
Why?
|
Mice | 2 | 2022 | 81183 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14722 | 0.010 |
Why?
|
Diet | 1 | 2019 | 7939 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2016 | 14557 | 0.010 |
Why?
|
Autoanalysis | 1 | 2000 | 72 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5985 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2000 | 159 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2000 | 224 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 21827 | 0.010 |
Why?
|
Mutation | 2 | 2014 | 29786 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12261 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.010 |
Why?
|
Eating | 1 | 2000 | 1536 | 0.010 |
Why?
|
Brain | 1 | 2016 | 26385 | 0.010 |
Why?
|
Models, Statistical | 1 | 1996 | 5102 | 0.000 |
Why?
|